Project Title: |
RTX4 Trial |
Project Type: |
Clinical Trial, Enrolment ongoing |
Disease group(s): |
Hereditary glomerulopathies, Immune glomerulopathies |
Project Summary: |
Efficacy of humanized chimeric monoclonal anti-CD20 antibodies (Rituximab Biosimilar) in the treatment of childhood steroid-dependent nephrotic syndrome and development of cell biomarkers predicting outcome. |
Lead principal investigator(s): |
, |
Co-investigator(s): |
Marina Vivarelli, Rome Francesco Emma, Rome |
Project Period: |
06/2019 - 06/2023 |
Sponsors: |
National funding agency |
EudraCT Nr.: |
2018-001042-33 |